Barclays
http://www.barclays.com/Barclays plc is a global financial services provider engaged in retail and commercial banking, credit cards, investment banking, wealth management and investment management services. It has an extensive international presence in Europe, the United States, Africa and Asia. In addition, the bank is one of the ten largest banks in the world measured by market capitalization. Barclays is headquartered in London, England.
-
Notable Analyst Rating Changes 06/12: (HMA) (AMAT) (RVBD) Upgraded; (BIIB) (LM) (USB) Downgraded
-
StreetInsider.com Pre-Open Movers 5/13: (THRX) (MTSN) (TSLA) Higher; (AFFY) (CEL) (UNXL) Lower (more...)
-
Market Wrap: Liberty Makes Virgin Deal Official; New Schedule for USPS; Barclays to Trim NY Jobs
-
Notable Analyst Rating Changes 11/21: (PENN) (THOR) (SKX) Upgraded; (HTWR) (EV) (ICA) Downgraded
-
Barclays on Healthcare: Top Takeaways from our Second Annual Therapeutics Symposium
-
Barclays Initiating Coverage: A Seamless Approach to Biopharmaceuticals
-
Notable Analyst Rating Changes 06/18: (MCP) (PCX) (MRVL) Upgraded; (SWKS) (CDXS) (RIMM) Downgraded
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
Barclays on Global Pharmaceuticals: Global Therapeutic Conference Preview: Multiple Sclerosis
-
Notable Analyst Rating Changes 04/25: (TZOO) (BIIB) (GE) Upgraded; (VECO) (SLM) (NUE) Downgraded
-
Notable 52-Week Highs and Lows of the Day 04/21: (SIRI) (UNH) (BIIB) High; (TEVA) (ZSTN) (AMR) Low
-
Barclays Maintains an 'Overweight' on Amgen (AMGN); Core Stable, XGEVA Strong, Strategy Next
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); PML Rate Change in 2011?
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); Initial Take on Laquinimod ALLEGRO Data
-
Notable Analyst Rating Changes 04/12: (LVLT) (EIX) (BIIB) Upgraded; (WMS) (AON) (CSX) Downgraded
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); PML Rate Normalizes
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); Strong 4Q10, Headwinds Persist in 2011
-
Barclays Maintains an 'Equalweight' on Elan Corp (ELN); Strong Gilenya Start May Translate to Tysabri Weakness
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); IMPACT RX Data Suggest Strong Gilenya Launch
-
Barclays Maintains an 'Equalweight' on Biogen (BIIB); PML Rate - It Did Not Stabilize
-
Barclays Maintains an 'Equalweight' on Biogen Idec (BIIB); Hemophilia Roundtable Update
-
Barclays on U.S. Biotechnology Weekly: Still Early in Biotech Upside Trade
-
Barclays Maintains an 'Equalweight' Rating on Biogen Idec (BIIB); Positive Data for Second Oral Competitor; Incremental Negative
-
Barclays Maintains an 'Equalweight' Rating on Biogen Idec (BIIB); 2Q Beats, But Potential Headwinds Ahead
-
Notable Analyst Rating Changes 1/5: RSH, QCOM, BIIB, AXL, More Upgraded; CBY, V, BEXP, COG, CXO, More Downgraded
-
David Moenning's Daily State of the Markets: If a Tree Falls In the Woods…
-
Stocks That Could Rise As Cases Of The Swine Flu Increase (RAD, GENZ, GILD, UTHR, XRAY)
-
Notable Analyst Rating Changes 6/29: DFS, LYG, TRW, BCS, JCP Upgraded; AA, SNY, BIIB, WW Downgraded
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Barclays Upgrades Biogen Idec (BIIB) to Equalweight
-
Barclays Downgrades Biogen (BIIB) to Underweight
-
David Moenning's Daily State of the Markets: 2/9
-
Notable Analyst Rating Changes 1/28: BBY, DO, CLX, AFL Upgraded; XOM, CNW, CIEN, UPS Downgraded
-
David Moenning's Daily State of the Markets: 1/27
-
Morning Movers 1/23: Wyeth (WYE) Higher On Bid Report; Microsemi (MSCC) Slammed On Results/Guidance
-
David Moenning's Daily State of the Markets: 01/05
